Physician profile
James Kelly
NPI 1659361848
$16,774.69
in general payments reported to CMS, 2019-2025
30 companies · $3,372 in 2025
The $3,372 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,659 · 2020: $1,154 · 2021: $1,471 · 2022: $1,969 · 2023: $3,224 · 2024: $1,926 · 2025: $3,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,472 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,472.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,120.63 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Clareon, Clareon Panoptix Pro |
| Carl Zeiss Meditec, INC. | $1,414.23 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $1,275.50 | 2019-2025 | Cequa, Xelpros |
| Harrow Eye, LLC | $905.67 | 2024-2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $865.83 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Bausch & Lomb Americas INC. | $709.31 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| New World Medical,INC. | $567.67 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $414.29 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $314.89 | 2024-2025 | Xdemvy |
| Allergan, INC. | $280.21 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $279.92 | 2019-2022 | |
| Rxsight INC | $244.05 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $230.35 | 2022-2025 | |
| Dompe US, INC. | $190.23 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $186.96 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $113.91 | 2021 | |
| Amgen INC. | $94.10 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.96 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $80.98 | 2022 | |
| Ocular Therapeutix, INC. | $58.48 | 2023 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $52.95 | 2024 | Clarus |
| Staar Surgical Company | $51.96 | 2019 | |
| Eyevance Pharmaceuticals LLC | $49.96 | 2022 | |
| Shire North American Group INC | $49.57 | 2019 | |
| Rayner Intraocular Lenses Limited | $47.88 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Sight Sciences, INC. | $35.53 | 2021-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $18.98 | 2023 | Tepezza |
| Genentech USA, INC. | $15.29 | 2024 | Vabysmo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$90,102.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.